These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
317 related articles for article (PubMed ID: 8666564)
1. Combination treatment with clomipramine and fluvoxamine: drug monitoring, safety, and tolerability data. Szegedi A; Wetzel H; Leal M; Härtter S; Hiemke C J Clin Psychiatry; 1996 Jun; 57(6):257-64. PubMed ID: 8666564 [TBL] [Abstract][Full Text] [Related]
2. Combination treatment with clomipramine and selective serotonin reuptake inhibitors for obsessive-compulsive disorder in children and adolescents. Figueroa Y; Rosenberg DR; Birmaher B; Keshavan MS J Child Adolesc Psychopharmacol; 1998; 8(1):61-7. PubMed ID: 9639080 [TBL] [Abstract][Full Text] [Related]
3. Fluvoxamine and clomipramine in depressed hospitalised patients: results from a randomised, double-blind study. Ottevanger EA Encephale; 1995; 21(4):317-21. PubMed ID: 7588171 [TBL] [Abstract][Full Text] [Related]
4. A double-blind study of fluvoxamine and clomipramine in the treatment of obsessive-compulsive disorder. Milanfranchi A; Ravagli S; Lensi P; Marazziti D; Cassano GB Int Clin Psychopharmacol; 1997 May; 12(3):131-6. PubMed ID: 9248868 [TBL] [Abstract][Full Text] [Related]
5. When fluvoxamine treats only depression and clomipramine treats only obsessive-compulsive disorder--combine them? Schaller JL; Behar D; Chamberlain T J Neuropsychiatry Clin Neurosci; 1998; 10(1):111-3. PubMed ID: 9547477 [No Abstract] [Full Text] [Related]
6. Addition of low-dose fluvoxamine to low-dose clozapine monotherapy in schizophrenia: drug monitoring and tolerability data from a prospective clinical trial. Szegedi A; Anghelescu I; Wiesner J; Schlegel S; Weigmann H; Härtter S; Hiemke C; Wetzel H Pharmacopsychiatry; 1999 Jul; 32(4):148-53. PubMed ID: 10505485 [TBL] [Abstract][Full Text] [Related]
7. Clomipramine demethylation rate is important on the outcome of obsessive-compulsive disorder treatment. Marcourakis T; Bernik MA; Lotufo Neto F; Gedanke Shavitt R; Gorenstein C Int Clin Psychopharmacol; 2015 Jan; 30(1):43-8. PubMed ID: 25279584 [TBL] [Abstract][Full Text] [Related]
8. Combined treatment with venlafaxine and tricyclic antidepressants in depressed patients who had partial response to clomipramine or imipramine: initial findings. Gómez Gómez JM; Teixidó Perramón C J Clin Psychiatry; 2000 Apr; 61(4):285-9. PubMed ID: 10830150 [TBL] [Abstract][Full Text] [Related]
9. Serum levels of clomipramine and desmethylclomipramine and clinical improvement in panic disorder. Marcourakis T; Gorenstein C; Ramos RT; da Motta Singer J J Psychopharmacol; 1999; 13(1):40-4. PubMed ID: 10221358 [TBL] [Abstract][Full Text] [Related]
10. Fluvoxamine as effective as clomipramine against symptoms of severe depression: results from a multicentre, double-blind study. Zohar J; Keegstra H; Barrelet L Hum Psychopharmacol; 2003 Mar; 18(2):113-9. PubMed ID: 12590404 [TBL] [Abstract][Full Text] [Related]
11. Multicentre, double-blind, comparison of fluvoxamine and clomipramine in the treatment of obsessive-compulsive disorder. Mundo E; Maina G; Uslenghi C Int Clin Psychopharmacol; 2000 Mar; 15(2):69-76. PubMed ID: 10759337 [TBL] [Abstract][Full Text] [Related]
12. Monitoring serum concentrations of clomipramine and metabolites: fluorescence polarization immunoassay versus high performance liquid chromatography. Banger M; Hermes B; Härtter S; Hiemke C Pharmacopsychiatry; 1997 Jul; 30(4):128-32. PubMed ID: 9271779 [TBL] [Abstract][Full Text] [Related]
13. Serum clomipramine and desmethylclomipramine levels in a CYP2C19 and CYP2D6 intermediate metabolizer. Brown JT; Schneiderhan M; Eum S; Bishop JR Pharmacogenomics; 2017 May; 18(7):601-605. PubMed ID: 28470111 [TBL] [Abstract][Full Text] [Related]
14. On the pharmacotherapy of obsessive-compulsive disorder: is a consensus possible? Todorov C; Freeston MH; Borgeat F Can J Psychiatry; 2000 Apr; 45(3):257-62. PubMed ID: 10779882 [TBL] [Abstract][Full Text] [Related]
15. Fluvoxamine. An updated review of its use in the management of adults with anxiety disorders. Figgitt DP; McClellan KJ Drugs; 2000 Oct; 60(4):925-54. PubMed ID: 11085201 [TBL] [Abstract][Full Text] [Related]